You are here: Home » PTI Stories » National » News
Business Standard

Marksans Pharma gets USFDA nod for Paricalcitol drug

Press Trust of India  |  New Delhi 

has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism.

"USFDA (US Food & Drug Administration) has granted approval for an abbreviated new drug application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg," said in a filing today.



Paricalcitol Capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules is a synthetic Vitamin D analog.

"Vitamin D is important for absorption of Calcium from the stomach and for functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism," the company said.

Shares of Marksans were trading 3.47 per cent up at Rs 55.10 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Marksans Pharma gets USFDA nod for Paricalcitol drug

Marksans Pharma has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism. "USFDA (US Food & Drug Administration) has granted approval for an abbreviated new drug application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg," Marksans Pharma said in a BSE filing today. Paricalcitol Capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg. Paricalcitol Capsules is a synthetic Vitamin D analog. "Vitamin D is important for absorption of Calcium from the stomach and for functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism," the company said. Shares of Marksans were trading 3.47 per cent up at Rs 55.10 apiece on BSE. has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism.

"USFDA (US Food & Drug Administration) has granted approval for an abbreviated new drug application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg," said in a filing today.

Paricalcitol Capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules is a synthetic Vitamin D analog.

"Vitamin D is important for absorption of Calcium from the stomach and for functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism," the company said.

Shares of Marksans were trading 3.47 per cent up at Rs 55.10 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Marksans Pharma gets USFDA nod for Paricalcitol drug

has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism.

"USFDA (US Food & Drug Administration) has granted approval for an abbreviated new drug application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg," said in a filing today.

Paricalcitol Capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules is a synthetic Vitamin D analog.

"Vitamin D is important for absorption of Calcium from the stomach and for functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism," the company said.

Shares of Marksans were trading 3.47 per cent up at Rs 55.10 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard